163 related articles for article (PubMed ID: 12903589)
1. [Molecular therapy of breast carcinoma in the advanced phase].
Foggi P; Amodio A
Tumori; 2003; 89(4 Suppl):189-91. PubMed ID: 12903589
[TBL] [Abstract][Full Text] [Related]
2. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
3. Growth factor receptors in breast cancer: potential for therapeutic intervention.
Nahta R; Hortobágyi GN; Esteva FJ
Oncologist; 2003; 8(1):5-17. PubMed ID: 12604728
[TBL] [Abstract][Full Text] [Related]
4. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.
Roussidis AE; Theocharis AD; Tzanakakis GN; Karamanos NK
Curr Med Chem; 2007; 14(7):735-43. PubMed ID: 17346159
[TBL] [Abstract][Full Text] [Related]
5. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
6. Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.
Pierobon M; Silvestri A; Spira A; Reeder A; Pin E; Banks S; Parasido E; Edmiston K; Liotta L; Petricoin E
J Proteome Res; 2014 Jun; 13(6):2846-55. PubMed ID: 24787230
[TBL] [Abstract][Full Text] [Related]
7. Targeting tyrosine kinases in cancer: the second wave.
Baselga J
Science; 2006 May; 312(5777):1175-8. PubMed ID: 16728632
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
9. [Molecular target therapy for malignant tumors].
Nihon Naika Gakkai Zasshi; 2005 Feb; 94 Suppl():76-80. PubMed ID: 15796061
[No Abstract] [Full Text] [Related]
10. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
13. [New molecules for therapeutic targets in cancer].
L'Allemain G; Bénard J
Bull Cancer; 2001 Dec; 88(12):1240-5. PubMed ID: 11792617
[No Abstract] [Full Text] [Related]
14. New drugs in cancer therapy, National Tumor Institute, Naples, 17-18 June 2004.
Caponigro F; Basile M; de Rosa V; Normanno N
Anticancer Drugs; 2005 Feb; 16(2):211-21. PubMed ID: 15655420
[TBL] [Abstract][Full Text] [Related]
15. Beyond Herceptin and Gleevec.
Fischer OM; Streit S; Hart S; Ullrich A
Curr Opin Chem Biol; 2003 Aug; 7(4):490-5. PubMed ID: 12941424
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors: a clinical perspective.
Goel S; Mani S; Perez-Soler R
Curr Oncol Rep; 2002 Jan; 4(1):9-19. PubMed ID: 11734109
[TBL] [Abstract][Full Text] [Related]
17. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
18. New targeted therapies in breast cancer.
Kaklamani V; O'Regan RM
Semin Oncol; 2004 Apr; 31(2 Suppl 4):20-5. PubMed ID: 15124130
[TBL] [Abstract][Full Text] [Related]
19. Added value of molecular targeted agents in oncology.
Soria JC; Blay JY; Spano JP; Pivot X; Coscas Y; Khayat D
Ann Oncol; 2011 Aug; 22(8):1703-16. PubMed ID: 21300696
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting tyrosine kinases: successes and limitations.
Arteaga CL
Cancer Biol Ther; 2003; 2(4 Suppl 1):S79-83. PubMed ID: 14508084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
